Tempus AI unit Ambry Genetics launches GenomeNext whole — genome sequencing test for rare diseases

Ambry Genetics, a Tempus AI subsidiary, launched GenomeNext, a whole-genome sequencing test aimed at improving rare-disease diagnosis. GenomeNext uses a pangenome reference to improve variant detection across diverse ancestral backgrounds. GenomeReveal adds integrated RNA analysis to support interpretation of certain DNA findings. Ambry’s Patient for Life program includes laboratory-initiated reanalysis, citing 5% positive reclassifications from prior negative or uncertain cases. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via (Ref. ID: 20261013424274) on October 13, 2026, and is solely responsible for the information contained therein. (C)